02:05 AM EDT, 05/06/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our target price to $125 from $111, 13.8x our 2026 EPS estimate, a discount to NBIX's historical forward P/E average, justified by the concentration risk in key drug Ingrezza sales. We lower our 2025 EPS estimate to $6.15 from $7.04 and our 2026 EPS view to $9.08 from $9.92. Neurocrine reported mixed Q1 2025 results with Q1 EPS down 41.7% Y/Y, due to lower-than-anticipated profitability. Yet, Q1 revenue rose by 1.1% Y/Y, driven by better-than-expected net product sales of key drug Ingrezza (+7.7% to $545.2M). The newly launched Crenessity for the treatment of kids and adults with congenital adrenal hyperplasia (CAH), generated $14.5M in its first full quarter of sales. We see the company's focus on advancing its clinical pipeline and expanding its commercial portfolio, with Crenessity as a strategic driver of long-term growth, albeit at the expense of near-term profitability. Yet, the Q1-end cash position remains solid at $944M, in our view, providing resources for R&D and commercial initiatives.